At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 196 enrolled
Drug / intervention
contezolid acefosamil +1 moredrug
Likely dose
linezolid 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection
In Brief
A Phase 2 clinical trial evaluating contezolid acefosamil and linezolid 600 mg for Skin Diseases, Bacterial and Gram-Positive Bacterial Infections. Completed, enrolled 196 participants across 7 sites.
Detailed Summary
The purpose of this study is to determine whether contezolid acefosamil is as safe and effective as linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedNov 20, 2018
Enrollment StartNov 15, 2018
Primary CompletionMar 26, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.6 years ago
Interventions
contezolid acefosamildrug
IV and oral contezolid acefosamil given twice a day for 10 to 14 days
linezolid 600 mgdrug
IV and oral linezolid given twice a day for 10 to 14 days